Fernández-Miranda C, Schoebel N, Angulo A, Paz-Ares L, Lianes P, del Palacio A
Servicio de Medicina Interna, Hospital Universitario Doce de Octubre, Madrid.
Rev Clin Esp. 1997 Jul;197(7):490-3.
To evaluate whether males with testicular cancer treated with chemotherapy including cisplatin (Qt-C) develop an increase in serum cholesterol and triglyceride levels and in the body mass index (BMI), which might pose a cardiovascular risk.
Fifty-six male patients with the previous diagnosis of testicular carcinoma, and apparently cured now, were studied. Thirty-six were Qt-C treated. The median age was 28 years and the median follow-up 81 months. The other 20 patients, with testicular cancer stage I and who did not require Qt-C, did not differ in mean age nor in the median of follow-up. Twenty healthy males were also studied, and their cholesterol and triglyceride levels and BMI were compared with those in patients treated with Qt-C at the end of follow-up; both group were of similar age. In all patients (prior to diagnosis and yearly up to the end of the study) and in healthy subjects total serum cholesterol and triglyceride levels were measured, as well as BMI (weight/height2).
Levels of cholesterol, triglycerides and BMI were not different at diagnosis of testicular cancer, both in patients treated with Qt-C and those not receiving such therapy. When comparing yearly cholesterol and triglyceride levels in both groups of patients during the first 6 years of evolution, no significant differences were observed. Again, no differences were observed between patients treated and not treated with Qt-C at the end of the follow-up period regarding cholesterol (211 +/- 41 vs 219 +/- 44 mg/dl; p = 0.51), triglyceride (128 +/- 57 vs 129 +/- 51 mg/dl; p = 0.94) and BMI (25.7 +/- 3.3 vs 25.5 +/- 3.4 kg/m2; p = 0.86) values. No significant differences were observed in the three parameters between parameters in patients treated with Qt-C at the end of follow-up and in healthy males.
In males with testicular cancer treated with Qt-C, no long term increase in cholesterol, triglyceride, and BMI values was detected, which might predispose to the development of cardiovascular diseases.
评估接受含顺铂化疗(Qt-C)的睾丸癌男性患者的血清胆固醇、甘油三酯水平及体重指数(BMI)是否升高,而这可能带来心血管风险。
研究了56例既往诊断为睾丸癌且目前看似已治愈的男性患者。其中36例接受了Qt-C治疗。中位年龄为28岁,中位随访时间为81个月。另外20例睾丸癌I期且无需Qt-C治疗的患者,其平均年龄和随访中位时间无差异。还研究了20名健康男性,并将他们的胆固醇、甘油三酯水平及BMI与随访结束时接受Qt-C治疗的患者进行比较;两组年龄相似。在所有患者(诊断前及直至研究结束每年)及健康受试者中,均测量了血清总胆固醇、甘油三酯水平以及BMI(体重/身高²)。
睾丸癌诊断时,接受Qt-C治疗的患者与未接受该治疗的患者相比,胆固醇、甘油三酯水平及BMI无差异。在病程的前6年比较两组患者每年的胆固醇和甘油三酯水平时,未观察到显著差异。同样,随访结束时,接受Qt-C治疗与未接受治疗的患者在胆固醇(211±41 vs 219±44 mg/dl;p = 0.51)、甘油三酯(128±57 vs 129±51 mg/dl;p = 0.94)和BMI(25.7±3.3 vs 25.5±3.4 kg/m²;p = 0.86)值方面也未观察到差异。随访结束时接受Qt-C治疗的患者与健康男性在这三个参数上也未观察到显著差异。
在接受Qt-C治疗的睾丸癌男性患者中,未检测到胆固醇、甘油三酯及BMI值的长期升高,而这可能易引发心血管疾病。